Published in Ghana Med J on September 01, 2013
Antiplasmodial properties of kaempferol-3-O-rhamnoside isolated from the leaves of Schima wallichii against chloroquine-resistant Plasmodium falciparum. Biomed Rep (2014) 0.89
IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells. Bioorg Med Chem (2014) 0.75
Cryptolepine inhibits melanoma cell growth through coordinated changes in mitochondrial biogenesis, dynamics and metabolic tumor suppressor AMPKα1/2-LKB1. Sci Rep (2017) 0.75
Herbal medicine research. Ghana Med J (2013) 0.75
Catechin Isolated from Garcinia celebica Leaves Inhibit Plasmodium falciparum Growth through the Induction of Oxidative Stress. Pharmacogn Mag (2017) 0.75
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med (1997) 14.51
p53: puzzle and paradigm. Genes Dev (1996) 13.16
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
Caspases: the executioners of apoptosis. Biochem J (1997) 11.99
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
Origin and physiological roles of inflammation. Nature (2008) 11.68
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Inhibition of NF-kappa B by sodium salicylate and aspirin. Science (1994) 7.60
The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev (1998) 7.46
Specific protection against breast cancers by cyclin D1 ablation. Nature (2001) 6.94
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol (2009) 5.05
Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science (1997) 4.37
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem (2003) 3.98
DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci U S A (1992) 3.50
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
Regulation of the immune response by prostaglandins. J Clin Immunol (1983) 3.12
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res (1998) 3.11
NF-kB in development and progression of human cancer. Virchows Arch (2005) 2.94
Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res (1994) 2.78
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res (1995) 2.74
Hormonal, cellular, and molecular control of prostatic development. Dev Biol (2003) 2.67
A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem (1998) 2.64
Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr (2004) 2.63
Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A (1996) 2.58
Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) (1998) 2.27
The multifaceted roles of nitric oxide in cancer. Carcinogenesis (1998) 2.19
Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell (1995) 2.13
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol (2000) 2.13
DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest (2002) 2.02
AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res (2001) 1.86
Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta (1998) 1.83
In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta. J Nat Prod (1997) 1.82
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 1.81
Insulin-like growth factors I and II. Eur J Biochem (1990) 1.74
NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis (2009) 1.71
Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem (2001) 1.64
The role of the insulin-like growth factor system in human cancer. Adv Cancer Res (1996) 1.52
Mycoplasma infections and different human carcinomas. World J Gastroenterol (2001) 1.48
Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol (1997) 1.45
Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta (2006) 1.44
Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis (2000) 1.36
v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem (1995) 1.35
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest (1995) 1.33
Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol (2001) 1.32
Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. J Pathol (1997) 1.30
Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol (2009) 1.29
Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta (1995) 1.26
Mutagenic properties of topoisomerase-targeted drugs. Biochim Biophys Acta (1998) 1.25
Insulin-resistance and benign prostatic hyperplasia: the connection. Eur J Pharmacol (2010) 1.24
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep (2008) 1.18
Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.17
Studies on cryptolepine. II: Inhibition of carrageenan induced oedema by cryptolepine. Planta Med (1981) 1.15
Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer (1999) 1.15
c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Mol Cell Biol (1997) 1.12
Clinical efficacy of a tea-bag formulation of cryptolepis sanguinolenta root in the treatment of acute uncomplicated falciparum malaria. Ghana Med J (2010) 1.12
The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nat Struct Biol (2002) 1.10
The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry (1998) 1.10
Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol (2001) 1.10
Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int (2007) 1.07
In vitro genotoxicity of the West African anti-malarial herbal Cryptolepis sanguinolenta and its major alkaloid cryptolepine. Toxicology (2005) 1.06
Cryptolepis sanguinolenta: an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. Diabet Med (1998) 1.05
Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog (1998) 1.05
NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim Biophys Acta (1999) 1.03
Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells. Evidence for post-transcriptional regulation. J Biol Chem (1996) 1.02
Mutagenesis associated with nitric oxide production in macrophages. Proc Natl Acad Sci U S A (1998) 1.00
Benign prostatic hyperplasia: dietary and metabolic risk factors. Int Urol Nephrol (2008) 0.98
Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res (2001) 0.91
The insulin-like growth factor system in the prostate. World J Urol (1995) 0.90
Apoptosis and heart failure: mechanisms and therapeutic implications. Am J Cardiovasc Drugs (2002) 0.89
Anti-inflammatory properties of cryptolepine. Phytother Res (2009) 0.89
Synthetic cryptolepine inhibits DNA binding of NF-kappaB. Bioorg Med Chem (2006) 0.88
Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol (2000) 0.87
The popular herbal antimalarial, extract of Cryptolepis sanguinolenta, is potently cytotoxic. Toxicol Sci (2002) 0.87
Mechanisms of induction of cell cycle arrest and cell death by cryptolepine in human lung adenocarcinoma a549 cells. Toxicol Sci (2006) 0.83
Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia (2001) 0.82
Synergism between heparin and adriamycin on cell proliferation and apoptosis in human nasopharyngeal carcinoma CNE2 cells. Acta Pharmacol Sin (2002) 0.82
[Correlation of benign prostatic hyperplasia with hyperlipemia]. Zhonghua Wai Ke Za Zhi (2005) 0.81
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients. Invest New Drugs (2008) 0.79
COX-2 inhibitors and the kidney. Hosp Pract (1995) (2001) 0.77
Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. Cancer Res (2000) 0.76
In vitro antimalarial interaction and transmission-blocking activity of cryptolepine. Planta Med (2016) 0.75